PictorLabs has filed a notice of an exempt offering of securities to raise $18,800,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, PictorLabs is raising $18,800,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Yair Rivenson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About PictorLabs
PictorLabs, Inc. is a digital pathology company developing an AI-powered virtual staining platform to revolutionize histopathology and accelerate clinical research with the goal of improving patient outcomes. Led by a team with deep expertise in bioengineering, artificial intelligence, and health-tech product development, the Company is reimagining existing histopathology workflows, accelerating clinical and diagnostic results, and improving process sustainability. From a single unstained tissue sample, PictorLabs proprietary platform can produce an unlimited number of virtual stains that are indistinguishable from analogous chemical stains. PictorLabs is developing products that replicate standard of care stains and is creating specialized virtual biomarker stains for indications in which there is a large demand for novel and accelerated diagnostic tests.
To learn more about PictorLabs, visit http://www.pictorlabs.ai/
Contact:
Yair Rivenson, Chief Executive Officer
601-568-3107
SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved